Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions

L. O. Murphy, M. W. Cluck, Sándor Lovas, F. Ötvös, R. F. Murphy, A. V. Schally, J. Permert, J. Larsson, J. A. Knezetic, T. E. Adrian

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

In-vitro and in-vivo studies have shown that autocrine growth factors and receptors are frequently expressed in human malignancies, Few of these studies, however, provide evidence that the identified autocrine pathway is functional, In this study, a functional autocrine growth pathway in pancreatic cancer has been identified using an in-vitro cell culture System. When pancreatic cancer cells were grown without change of medium, proliferation was greater than when either medium was replaced frequently (HPAF, CAPAN-2, PANC-1 or SW1990) or cells were grown in the presence of the EGF receltor tyrosine kinase inhibitor AG1478 or the MEK inhibitor PD098059 (HPAF or CAPAN-2). Activity of extracellurar-regulated kinases (ERK) 1 and 2 and c-jun and c-fos mRNA levels were significantly elevated in CAPAN-2 cells cultured continuously in serum-free medium, Collectively, the observations indicate that the EGF receptor and the ERK MAP kinase pathway mediate autocrine signals. In contrast to previous reports, the GRP and IGF-I receltors were shown not to be required for autocrine effects on pancreatic cancer cell proliferation, Autocrine stimulation of the EGF receltor can contribute to sustained mitogenic activity and proliferation of pancreatic cancer cells.

Original languageEnglish
Pages (from-to)926-935
Number of pages10
JournalBritish Journal of Cancer
Volume84
Issue number7
DOIs
StatePublished - Apr 6 2001

Fingerprint

Pancreatic Neoplasms
Epidermal Growth Factor Receptor
Mitogen-Activated Protein Kinase Kinases
Serum
Epidermal Growth Factor
Mitogen-Activated Protein Kinase 9
Mitogen-Activated Protein Kinase 8
Growth Factor Receptors
Serum-Free Culture Media
Insulin-Like Growth Factor I
Protein-Tyrosine Kinases
Cultured Cells
Cell Culture Techniques
Cell Proliferation
Messenger RNA
Growth
Neoplasms
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. / Murphy, L. O.; Cluck, M. W.; Lovas, Sándor; Ötvös, F.; Murphy, R. F.; Schally, A. V.; Permert, J.; Larsson, J.; Knezetic, J. A.; Adrian, T. E.

In: British Journal of Cancer, Vol. 84, No. 7, 06.04.2001, p. 926-935.

Research output: Contribution to journalArticle

Murphy, LO, Cluck, MW, Lovas, S, Ötvös, F, Murphy, RF, Schally, AV, Permert, J, Larsson, J, Knezetic, JA & Adrian, TE 2001, 'Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions', British Journal of Cancer, vol. 84, no. 7, pp. 926-935. https://doi.org/10.1054/bjoc.2001.1698
Murphy, L. O. ; Cluck, M. W. ; Lovas, Sándor ; Ötvös, F. ; Murphy, R. F. ; Schally, A. V. ; Permert, J. ; Larsson, J. ; Knezetic, J. A. ; Adrian, T. E. / Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. In: British Journal of Cancer. 2001 ; Vol. 84, No. 7. pp. 926-935.
@article{5c7d205e5785472686ad78fc38110105,
title = "Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions",
abstract = "In-vitro and in-vivo studies have shown that autocrine growth factors and receptors are frequently expressed in human malignancies, Few of these studies, however, provide evidence that the identified autocrine pathway is functional, In this study, a functional autocrine growth pathway in pancreatic cancer has been identified using an in-vitro cell culture System. When pancreatic cancer cells were grown without change of medium, proliferation was greater than when either medium was replaced frequently (HPAF, CAPAN-2, PANC-1 or SW1990) or cells were grown in the presence of the EGF receltor tyrosine kinase inhibitor AG1478 or the MEK inhibitor PD098059 (HPAF or CAPAN-2). Activity of extracellurar-regulated kinases (ERK) 1 and 2 and c-jun and c-fos mRNA levels were significantly elevated in CAPAN-2 cells cultured continuously in serum-free medium, Collectively, the observations indicate that the EGF receptor and the ERK MAP kinase pathway mediate autocrine signals. In contrast to previous reports, the GRP and IGF-I receltors were shown not to be required for autocrine effects on pancreatic cancer cell proliferation, Autocrine stimulation of the EGF receltor can contribute to sustained mitogenic activity and proliferation of pancreatic cancer cells.",
author = "Murphy, {L. O.} and Cluck, {M. W.} and S{\'a}ndor Lovas and F. {\"O}tv{\"o}s and Murphy, {R. F.} and Schally, {A. V.} and J. Permert and J. Larsson and Knezetic, {J. A.} and Adrian, {T. E.}",
year = "2001",
month = "4",
day = "6",
doi = "10.1054/bjoc.2001.1698",
language = "English",
volume = "84",
pages = "926--935",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions

AU - Murphy, L. O.

AU - Cluck, M. W.

AU - Lovas, Sándor

AU - Ötvös, F.

AU - Murphy, R. F.

AU - Schally, A. V.

AU - Permert, J.

AU - Larsson, J.

AU - Knezetic, J. A.

AU - Adrian, T. E.

PY - 2001/4/6

Y1 - 2001/4/6

N2 - In-vitro and in-vivo studies have shown that autocrine growth factors and receptors are frequently expressed in human malignancies, Few of these studies, however, provide evidence that the identified autocrine pathway is functional, In this study, a functional autocrine growth pathway in pancreatic cancer has been identified using an in-vitro cell culture System. When pancreatic cancer cells were grown without change of medium, proliferation was greater than when either medium was replaced frequently (HPAF, CAPAN-2, PANC-1 or SW1990) or cells were grown in the presence of the EGF receltor tyrosine kinase inhibitor AG1478 or the MEK inhibitor PD098059 (HPAF or CAPAN-2). Activity of extracellurar-regulated kinases (ERK) 1 and 2 and c-jun and c-fos mRNA levels were significantly elevated in CAPAN-2 cells cultured continuously in serum-free medium, Collectively, the observations indicate that the EGF receptor and the ERK MAP kinase pathway mediate autocrine signals. In contrast to previous reports, the GRP and IGF-I receltors were shown not to be required for autocrine effects on pancreatic cancer cell proliferation, Autocrine stimulation of the EGF receltor can contribute to sustained mitogenic activity and proliferation of pancreatic cancer cells.

AB - In-vitro and in-vivo studies have shown that autocrine growth factors and receptors are frequently expressed in human malignancies, Few of these studies, however, provide evidence that the identified autocrine pathway is functional, In this study, a functional autocrine growth pathway in pancreatic cancer has been identified using an in-vitro cell culture System. When pancreatic cancer cells were grown without change of medium, proliferation was greater than when either medium was replaced frequently (HPAF, CAPAN-2, PANC-1 or SW1990) or cells were grown in the presence of the EGF receltor tyrosine kinase inhibitor AG1478 or the MEK inhibitor PD098059 (HPAF or CAPAN-2). Activity of extracellurar-regulated kinases (ERK) 1 and 2 and c-jun and c-fos mRNA levels were significantly elevated in CAPAN-2 cells cultured continuously in serum-free medium, Collectively, the observations indicate that the EGF receptor and the ERK MAP kinase pathway mediate autocrine signals. In contrast to previous reports, the GRP and IGF-I receltors were shown not to be required for autocrine effects on pancreatic cancer cell proliferation, Autocrine stimulation of the EGF receltor can contribute to sustained mitogenic activity and proliferation of pancreatic cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=17744386907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744386907&partnerID=8YFLogxK

U2 - 10.1054/bjoc.2001.1698

DO - 10.1054/bjoc.2001.1698

M3 - Article

VL - 84

SP - 926

EP - 935

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -